Ibrutinib Combo in Chronic Lymphocytic Leukemia is Superior, but Costly

While  ibrutinib plus rituximab may improve progression-free survival in chronic lymphocytic leukemia, it is a costly option for some patients.

Source: CancerNetwork - September 3, 2019 Category: Cancer & Oncology Authors: Christina Bennett, MS Source Type: news